NCT04274738 2024-08-27A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4X4 PharmaceuticalsPhase 1 Completed16 enrolled